Protontherapy is hadrontherapy's fastest-growing modality and a pillar in the battle against cancer.
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The urgent need for radical radiotherapy research to achieve improved tumour control in the context of reducing the risk of normal tissue toxicity and late-occurring sequelae, has driven the fastgrowing development of cancer treatment by accelerated beams of charged particles (hadrontherapy) in recent decades (1). This appears to be particularly true for protontherapy, which has emerged as the most-rapidly expanding hadrontherapy approach, totalling over 100,000 patients treated thus far worldwide (2) . The use of energetic protons for cancer radiotherapy was first proposed by Wilson in 1946 (3) . The primary motivation for investigation into this area was based on the physical properties of charged particles, which can deposit energy far more selectively than photons: through the inverted depth-dose profile described by the Bragg curve (4), healthy tissues within the entry channel of the beam are spared of dose, while most of the dose is steeply confined at the end of the particle range (the so-called "Bragg peak"). This in principle enables the delivery of very high-dose gradients close to organs at risk, confining the high-dose area to the tumour volume. Despite the dearth of randomized trials showing an effective advantage of protons over photon-based radiotherapy (5, 6) and the ongoing debate over its cost-effectiveness (7) , the current phase I/II clinical results support the rationale of the approach, especially for deep-seated tumours localized in proximity of critical organs, and unresectable or recurrent tumours (8, 9) . Cancer treatment by protons also remains the most attractive solution in the case of paediatric patients due to the significant reduction in the integral dose delivered to the patient (8) , even compared to newer photon techniques such as intensity modulated radiation therapy (10) . However, protons have been traditionally regarded as only slightly more biologically effective than photons (11) . In fact, the standard practice in protontherapy is to adopt an RBE (Relative Biological Effectiveness) value of 1.1 compared to photons in any clinical condition (12) , although such an assumption overlooks the increased RBE of low-energy protons (13) (14) (15) disregarding recently unveiled peculiarities of proton radiobiology (8, 16, 17) .
The combination of ballistic precision with an increased ability to kill cells is the radiobiological rationale currently supporting the clinical exploitation of heavier particles such as fully stripped 3 12 C-ions (19) , which present some advantages over protons (6, 19) . Not only do they ensure a better physical dose distribution, due to less lateral scattering (20) , but they are also more biologically effective both in vitro and in vivo as a result of their higher Linear Energy Transfer (LET) (11, 21, 22) . In fact, densely ionizing radiation tracks cause more spatio-temporally contiguous and complex lesions at the DNA level, comprising DNA double-strand breaks and damaged bases, which are highly clustered in nature (23) (24) (25) . This impairs cellular ability for correct repair (26) and decreases the dependence of radiosensitization upon the presence of oxygen, desirable features for eradication of resilient, hypoxic tumors (5, 27) . Further potential radiobiological advantages include greater RBE for killing putatively radioresistant cancer stem cells (28) and counteracting cancer invasiveness (29, 30) , albeit the latter remains controversial (31) . Finally, low doses of high-LET radiation appear to elicit stronger immunological responses compared to low-LET radiation (17) .
On the other hand, nuclear fragmentation reactions incurred by the primary beam partially spoil the 12 C superior dose distribution, depositing unwanted dose behind the target volume, as opposed to the sharp dose fall-off that characterizes protons (32) . Moreover, there exists a substantial lack of understanding of the impact on normal cells of the exposure to high-LET radiation. While it is true that preliminary reports on the follow-up of patients treated with 12 C ions do not show an increased incidence of secondary cancers (33) , uncertainties surround the effectiveness with which high-LET radiations such as 12 C ions cause non-cancer effects that can have clinical repercussions. As a matter of fact, mounting evidence seems to indicate that 12 C ions are particularly effective at causing pro-inflammatory responses leading to cardiovascular complications and premature cellular senescence even at low doses, i.e. those absorbed by the traversed healthy tissues (34) (35) (36) . Taken together, these findings warrant further radiobiological investigation on the possible after effects arising from 12 C hadrontherapy. Finally, a major hindrance to a greater diffusion of 12 C hadrontherapy, which remains limited to a few centres, is caused by the complexity of their acceleration, transport and handling, delivery to the patient and dosimetry. These are more complicated compared to proton beams, leading to an increase of the initial investment and overall running costs of 12 C-ion therapy centers (37) .
In order to overcome such limitations, different strategies are being explored with the aim to achieve alternative solutions for a localized increase of proton RBE. One of the recently proposed approaches foresees the use of gold nanoparticles as protontherapy radiosensitizers (38) . The ability of particle radiation to stimulate favourable immunological responses represents another attractive solution as it has become increasingly evident that proton and photon irradiation differentially modulate systemic biological responses (8, 17) .
In this work, we experimentally demonstrate for the first time that the p + 11 B à3a nuclear fusion reaction, which is known to generate short-range high-LET alpha particles (39, 40) , can be exploited to enhance proton biological effectiveness exclusively in the tumour region, and thus is of potential clinical worth. Cells were irradiated with a clinical proton beam in the presence of sodium borocaptate (NA 2 B 12 H 11 SH or "BSH"), which is a common agent used in BNCT) in its 10 Benriched form to selectively deliver boron in cancer cells (41) . BNCT requires thermal neutrons to trigger the reaction where a single alpha particle with maximum energy of around 2.7 MeV and range in tissue of less than 10 µm is produced (42) . In order to maximize the p + 11 B à3a fusion rate, we used the compound with natural occurring boron isotopic abundance (i.e. 80% 11 B and 20% 10 B). We observed a significant increase in proton-induced cytogenetic effects, both in terms of cell death, assessed as loss of proliferative potential by the clonogenic cell survival, and of induction of DNA damage. The latter was studied by chromosome aberrations revealed by Fluorescence-in Situ Hybridization (FISH) painting. Specifically, the markedly higher frequency of complex-type chromosome exchanges (a typical cytogenetic signature of high-LET ionizing radiation, see ref. 43 for example), which was found among boron-treated cells compared to proton-irradiated cells in the absence of BSH, points to the alpha particles generated in the nuclear fusion reaction as being 5 responsible for the measured enhancement of proton biological effectiveness. These findings, therefore, yield important implications for cancer protontherapy.
Results

Experimental approach
The proton-boron nuclear reaction considered in this work is usually formalized as p+ 11 
It has a positive Q-value (8.7 MeV) and is often referred to as the "proton-boron fusion reaction", as the incident proton is completely absorbed by the 11 B nucleus. This reaction has garnered interest since the 1930s (39, 40) because of the process' ability to produce copious numbers of alpha particles in an exothermic reaction.
According to the most recent studies and interpretations, p+ 11 B -> 3α can be basically described as a two-step reaction (involving 12 C and 8 Be nuclei excitation) with a main resonance occurring at a 675 keV (center of mass energy) and where the maximum cross section of 1.2 barn is measured (44, 45) . A more detailed description of the reaction is reported in Methods.
The emitted alpha particles exhibit a wide energy spectrum with a predominant energy around 4
MeV (46) . Such a reaction has been considered very attractive for the generation of fusion energy without producing neutron-induced radioactivity (47, 48) .
Such a nuclear reaction may be even more useful as it could play a strategic role in medical applications improving the effectiveness of protontherapy. The potential clinical use of the p-11 B reaction has thus far only been theoretically investigated (49) . Here we experimentally implement for the first time this innovative approach and actually measure the biological effects elicited by such a reaction.
Besides the advantage of using a neutron-free nuclear reaction, the value of this method is also based on the fact that the the p + 11 B à3α cross section becomes significantly high at relatively low incident proton energy, i.e. around the Bragg peak region. As schematically depicted in Fig.1 , a 6 conventional proton beam used in protontherapy is drastically slowed down across the tumour, corresponding to the Bragg peak region. Thus, most of its energy (dose) is delivered to the tumour cells. Assuming a given concentration of 11 B nuclei is present preferentially, but not exclusively, in the tumour, the presence of slow protons could trigger a series of fusion events generating alpha particles localized in the tumour region. In fact, most of the alpha particles generated in the protonboron reaction have an average range in water of less than 30 µm, comparable with typical cell size.
Hence, even if such particles are mainly produced outside the cell cytoplasm due to sub-optimal boron uptake, the probability that they would reach the nucleus and damage the DNA remains very high. Moreover, even if a non-negligible concentration of 11 B nuclei is present in the healthy tissues surrounding the tumour, the number of fusion events (i.e. generated alpha particles), will be relatively low or completely absent due the non-favourable incident proton energy fluence away from the tumour region. This would lead to a more biologically effective particle dose localization, higher than that currently achievable with conventional protontherapy, thus to a more efficient treatment in terms of an increase in cancer cell lethality because of the clustered nature of the DNA damage caused by the high-LET alpha particles emitted in the tumour region. Hence, protontherapy could acquire the benefits of an enhanced RBE for cancer cell killing, similar to 12 C ion hadrotherapy but without the above-mentioned complications of the latter. The dose in protontherapy is currently released mainly in the tumor region (upper panel), cancer cells being represented here by purple circles and damaging events by black dots (A): protoninduced damage is similar to that imparted to DNA by photons, consisting mainly of isolated lesions (middle and lower panels). If cancer cells are loaded with 11 B-delivering agents (middle panel, B), as is the case with 10 B-enriched compounds in BNCT, unrepairable DNA clustered lesions will be also produced by the high-LET alpha particles generated by the p-11 B nuclear fusion reaction (lower panel). This in turn leads to the achievement of a greater RBE for cancer cell killing while maintaining beneficial sparing of surrounding healthy tissues (middle panel).
Figure 1 | Schematic representation of "conventional" radiotherapy by low-LET proton beams (A) and the rationale of boron-enhanced protontherapy (B).
Proton therapy pB therapy
BSH enhances cancer cell death following proton-irradiation
To test whether the p + 11 As a control, prostate cancer DU145 cells grown and irradiated without BSH were used. The considered BSH concentrations were equivalent to 40 ppm (parts per million) and 80 ppm of 11 B.
These were chosen based on values from the literature on the 10 B-enriched BSH analogue used in BNCT in order to achieve the optimal 10 B concentration (41, 50, 51) . In particular, similar boronequivalent concentration ranges of another BNCT compound, BPA, had been previously used with the same cell line in vitro (52) . Boron treatment enhanced proton irradiation biological effectiveness resulting in a significant increase in the induction of cell death in DU145 cells as measured by loss of colony-forming ability. Cells that were irradiated after pre-treatment with, and in the presence of, boron-containing BSH exhibited a greater radiosensitivity in comparison with cells exposed to radiation alone: BSH-treated cells yielded a much steeper clonogenic dose-response curve than that obtained for cells grown and irradiated in BSH-free medium (Fig. 2) . The magnitude of radiationinduced cell death was not affected by boron concentration. In our hands, the clonogenic survival 9 fraction SF was best fitted to a linear function of dose, i.e. SF = exp (-a*D). Measured survival curve parameters were a = (0.79 ± 0.04) Gy -1 for 80 ppm of 11 B and a = (0.36 ± 0.06) Gy -1 for the dose response curve obtained in the absence of BSH, with a calculated RBE 10 of 1.8. This indicated that protons in the presence of the boron compound were almost twice as effective at reducing cell survival by 90% compared to proton irradiation alone. Cellular radiosensitivity following low-LET proton irradiation was identical to that recorded after X-rays ( Fig.2) . At the concentrations used, BSH was not cytotoxic since the proliferative potential of unirradiated cells as given by cellular plating efficiency was not affected by the presence of BSH (Table 1 ). This means that the measured enhancement of proton effectiveness at cell killing was not contributed to by cytotoxicity caused by the boron-containing compound per se. Similarly, the recorded frequency of CAs in cells not exposed to radiation is referred to as baseline CA frequency.
Induction and complexity of proton irradiation-induced DNA damage are exacerbated by BSH
Radiation-induced structural chromosome aberrations (CAs) arise from mis-or un-rejoined DNA breaks due to erroneous repair (53, 54) . Ionizing radiation can give rise to a wide spectrum of aberration types (55) . Complex-type exchanges, defined as those rearrangements involving at least two chromosomes and generated by at least three breaks, are an archetypical feature of high-LET exposure (43, 56) . Measurement of CA frequency and, in particular, quantification of the proportion of complex-type chromosome exchanges was therefore instrumental to assess a possible increase in radiation-induced genotoxicity and whether this could be ascribed to high-LET alpha particles generated by the BSH-assisted p + 11 B à3α nuclear reaction. Cancer cells are known to be genetically unstable, hence they do not lend themselves to reliable assessment of radiation-induced DNA damage. Radiation-induced chromosome rearrangements would superimpose onto an elevated confounding frequency of baseline damage. Therefore, the non-tumorigenic breast epithelial MCF-10A cell line was chosen for scoring of radiation induced CAs. Proton irradiation resulted in a higher CA frequency in cells treated with BSH compared to cells irradiated with protons in the absence of BSH (Fig. 3 ). 11 B concentration did not affect the measured frequency of radiationinduced CA as shown by the similar induction of DNA damage between 40 ppm and 80 ppm of 11 B.
In addition, in cells not exposed to radiation, BSH per se did not cause significantly higher genotoxic damage compared BSH-untreated cells ( Table 1 ). The yield of CAs following X-rays was basically identical to that measured after exposure to protons in the absence of BSH (Fig. 3) .
Aberration data were fitted to a linear -quadratic function of the type Y= Y 0 +a*D+b*D 2 where the coefficient Y 0 corresponded to the baseline CA frequency as reported in Table 1 Data points correspond to the mean value measured in two independent experiments with standard errors of counts.
Interestingly, a markedly pronounced occurrence of complex-type exchanges was found in samples treated with BSH compared to cells that had been irradiated with protons in the absence of BSH 13 (Fig. 4 ). After 0.5 Gy of protons the frequency of complex CAs ranged between 0.025 and 0.028 for BSH-treated cells as opposed to less than 0.004 in the case of cells irradiated in the absence of BSH.
These values dramatically increased with dose and remained consistently higher in the case of BSHtreated cells, reaching about 0.18 and 0.08 after 4 Gy of protons in the presence or the absence of BSH, respectively. Occurrence of complex-type exchanges following X-rays is also shown for comparison ( Fig. 4) and does not differ from that measured for proton irradiation alone. BNCT has never quite fulfilled its potential as a powerful cancer treatment modality both because of the intrinsically challenging quest for ideal carriers to deliver radiobiologically effective concentrations of boron to cancer cells, and of the availability of thermal neutron sources (41, 51) .
On the other hand, albeit already being a clinical reality, external beam 12 C-ion hadrontherapy, which is capable of delivering very biologically effective radiation doses with extremely high precision to the tumor target, is hampered by economic and radiobiological issues as illustrated in the Introduction.
Currently, the most widespread form of cancer treatment by accelerated charged particles is represented by protontherapy, which guarantees the same ballistic precision as 12 in human lymphocytes at the highest dose of thermal neutrons used by them (i.e. 0.248 Gy) and at a similar 11 B-equivalent concentration (30 ppm). In addition, a significantly higher proportion of complex chromosome rearrangements in BSH-treated cells compared to controls following proton irradiation was found pointing to an LET-dependent effect since complex CAs are a well-known cytogenetic signature of exposure to high-LET radiation. In fact, it is well known that the greater biological effectiveness of densely ionizing radiation is a direct consequence of the physical pattern of energy deposition events along and around its tracks. Low-LET ionizing radiation such as x-or g-rays mainly damage cells through short-lived bursts of free radicals (e.g. reactive oxygen species), generated by its interaction with the intracellular environment. This causes isolated lesions at the DNA level, the most detrimental of which for cell survival are double-strand breaks (DSBs).
However, the much denser thread of ionization events specific to track-structured high-LET particle radiations, results in many closely spaced clusters of multiply DNA damaged sites, comprising
DSBs together with single-strand breaks and damaged bases, which cause the cellular repair system to be error-prone. Hence, such lesions either are left unrepaired, which explains the greater efficiency of high-LET radiations at cell killing, or undergo misrepair. In the latter case, since single densely ionization tracks can simultaneously cause breaks in far apart stretches of DNA, i.e.
belonging to separate chromosome domains, defective repair will lead to a higher frequency of DNA mis-rejoining events occurring between several chromosomes that after low-LET radiation, the so-called complex-type exchanges. In BSH-treated irradiated cells, the proportion of such complex-type aberrations relative to total exchanges ranged between 30% and 42% while that for proton irradiation alone was between 6% and 15%. Moreover, the ratio of complex-to simpleexchanges found by us ranged between 0.59 and 0.71, similar to the figure of 0.64 found by others for 0.5 Gy of direct alpha particle irradiation in first-division human lymphocytes scored with the same technique used by us, i.e. FISH painting (61).
We did not perform measurements of actual 11 B incorporation by cells but both drug pre-treatment times and concentrations were chosen according to available literature in BNCT studies showing the best conditions to achieve the ideal boron concentration in cells (20 µg per grams of tissue or 10 9 atoms per cell). Indeed, although 10 B-enriched BSH is known for its poor permeabilization through cell membranes, its use is facilitated by the higher boron content compared to the other widely used boron-delivering compound, BPA. However, the alpha particles emitted via the p + 11 B
à3α reaction have average energies around 4 MeV corresponding to ranges in tissues of a few tens of microns, which ensures that severe cellular DNA damage is caused even if BSH is not 18 incorporated in the cell but sits on its membrane. Moreover, the ballistic properties of the incident proton beam whereby proton energies drastically decrease in correspondence with the tumour volume, ensure negligible nuclear fusion events even in the worst-case scenario where the delivery agent containing 11 B nuclei is also present in the healthy tissues surrounding the tumour.
Furthermore, the presence of 10 B in the proposed method allows to trigger different nuclear reactions generating prompt gamma-rays, which could be potentially used in a simultaneous treatment-and-diagnostics approach (49, 62, 63) .
In conclusion, if further confirmed by both in vitro and pre-clinical investigations, our results represent an important breakthrough in cancer radiotherapy, particularly in the treatment of the disease by accelerated proton beams since it may significantly enhance its effectiveness without foreseeable patients' health complications and added financial costs. 
p + 11 B à3α nuclear fusion
The p + 11 B à3α nuclear fusion reaction at low energy can be basically described as a two-step reaction due to its behaviour at the three resonant energies (0.162 MeV, 0.675 MeV and 2.64 MeV).
Firstly, a proton, interacting with 11 B, induces the formation of a 12 C* compound nucleus formed in the 2-or 3-excited state. If the 12 C* nucleus is formed in its 2-state, it will decay to the first 2+ state of 8 Be emitting one alpha-particle with l = 3 (65) . If the 12 C* nucleus is formed in its 3-state, then the primary alpha particle can be emitted either with l = 1 from the decay to the first 2+ 8 Be excited state, or with l=3 from the decay to the 0+ 8Be ground state. In either case, the remaining 8 Be (2+ or 0+) nucleus immediately decays into two secondary alpha-particles with l' = 2. Alpha particles emitted in the first stage present a well-defined energy distribution and are commonly 20 referred to as α0 and α1 if the 8 Be 2+ or the 0+ states are populated, respectively. A few authors (65, 66) report that a very unlikely fourth channel, characterized by a maximum cross section of 10 µb in the 2.0 -2.7 MeV energy range (66) , can also be activated. In this case the 12 C* directly breaks into three a particles skipping the intermediate 8 Be stage, which show a continuous energy distribution. Figure 5 reports some of the available experimental data (65, 66) for the total production cross section of the p + 11 B à3α reaction as function of the mass centre energy and for the a 1 channel. For low energies (0.1-5
MeV) the reaction cross sections become significantly high, thus maximising the alpha particle production around the proton Bragg peak region, an advantageous feature for the alternative protontherapy approach proposed in this work. Measurement of cell death. Radiation-induced cell death was assessed by means of the clonogenic test, the gold standard for measuring cellular radiosensitivity. According to this assay, a cell survives irradiation if it retains its proliferative potential and it is thus capable of forming a colony composed of at least 50 cells.
After irradiation, the medium was discarded from the flasks, and DU145 cells were detached, counted by haemocytometer and re-plated at opportune densities. They were then allowed to grow for colony formation in BSH-free medium. Four replicates for each dose were used for statistical data robustness. Clones were were incubated for 30 min with calyculin A (50 ng/mL, Sigma-Aldrich) for PCC induction as elsewhere described (70) . To collect PCC spreads, cells were trypsinized, centrifuged at 300g for 8 min, then the pellet was resuspended for 25 min in hypotonic solution (75 mM KCl at 37°C), and fixed on ice in freshly prepared Carnoy solution (3:1 v/v methanol/acetic acid). Spreads were then dropped on pre-warmed (42 °C) wet slides and air-dried at room temperature. Fluorescence In Situ Hybridization painting was conducted by using whole-chromosome fluorescence-labelled DNA painting probes directed to chromosomes 1 and 2 following the manufacturer's recommendations (MetaSystems, Germany). Denaturation (72°C for 3 min) followed by hybridization (37°C overnight) of slides was performed using a hand-free HYBrite chamber system. Unlabeled chromosomes were counterstained with 12 ml 4,6-diamidino-2-phenylindole (DAPI) staining. Slides were viewed with an epi-fluorescence microscope connected to a computer-controlled system (Metafer 4 software, MetaSystems,) for automated slide scanning and three-color image acquisition.
Chromosome analysis was carried out on stored images. Scoring was conducted blind by the same scorer.
Not less than 500 chromosome spreads for each dose were scored (at least 1,500 for nonirradiated controls).
All types of aberrations were scored separately and categorized as simple exchanges (i.e. translocations and dicentrics), either complete or incomplete, acentric fragments and complex exchanges. For this study's purpose, however, data herein presented are relative to the total chromosomal exchange frequency and to the complex-type exchange frequency. Frequency of total aberration exchanges was fitted to the equation Y = Y 0 +a*D+bD 2 .
Statistical analysis
For analysis of the dose -response relationships for cell killing and chromosome aberration frequency, curve fitting was performed by nonlinear least square minimization (Marquardt's algorithm) using SigmaPlot 12.5 software (SPSS, USA). Poisson statistics was assumed to derive standard errors on aberration frequencies.
Experimental surviving fraction data in clonogenic assays are affected by several sources of errors, such as those associated with cell counts and cell dilutions, which are not taken into account by simple calculations of the standard error affecting colony counting. A more precise approach is needed to determine the experimental error on the plating efficiency PE as above defined and here recalled for convenience: In the interest of simplicity, it can be assumed that the mean number of cells seeded that appears in the above formula is devoid of error, which is is reasonable since cell counting error is taken care of in the SE (PE) .
This means treating &+((, as a constant; hence we can define In these calculations we assumed that observed CV is always greater than Poisson CV on all counts, of either colonies or cells; wherever this was no the case, we corrected the experimental SE by multiplying the mean (of cell or colony counts) by the Poisson CV.
